Raymond James Has Lowered Expectations for Crescent Capital BDC (NASDAQ:CCAP) Stock Price

Crescent Capital BDC (NASDAQ:CCAP) had its target price reduced by equities researchers at Raymond James from $20.00 to $17.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Raymond James’ price target suggests a potential upside of 10.25% from the company’s previous close.

A number of other research firms have also recently weighed in on CCAP. Wells Fargo & Company cut their price target on Crescent Capital BDC from $16.00 to $15.00 and set an “equal weight” rating on the stock in a report on Friday. Keefe, Bruyette & Woods cut Crescent Capital BDC from an “outperform” rating to a “market perform” rating and cut their price target for the company from $18.50 to $17.00 in a report on Friday. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $17.60.

Crescent Capital BDC Stock Down 3.3%

NASDAQ:CCAP opened at $15.42 on Friday. The company has a market capitalization of $571.47 million, a price-to-earnings ratio of 7.75 and a beta of 0.63. Crescent Capital BDC has a one year low of $13.54 and a one year high of $20.19. The stock has a 50-day simple moving average of $16.19 and a 200 day simple moving average of $18.07. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.26 and a current ratio of 1.32.

Crescent Capital BDC (NASDAQ:CCAP) last issued its earnings results on Wednesday, May 14th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.52 by ($0.07). Crescent Capital BDC had a return on equity of 11.90% and a net margin of 37.32%. The business had revenue of $42.13 million during the quarter, compared to the consensus estimate of $45.08 million. Sell-side analysts predict that Crescent Capital BDC will post 2.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Crescent Capital BDC

Large investors have recently bought and sold shares of the business. Montag A & Associates Inc. bought a new stake in Crescent Capital BDC in the fourth quarter worth $35,000. C M Bidwell & Associates Ltd. acquired a new position in Crescent Capital BDC during the 4th quarter worth $39,000. Aquatic Capital Management LLC acquired a new position in Crescent Capital BDC during the 4th quarter worth $129,000. Generation Capital Management LLC acquired a new position in Crescent Capital BDC during the 4th quarter worth $192,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Crescent Capital BDC during the 4th quarter worth $218,000. 49.46% of the stock is currently owned by institutional investors.

About Crescent Capital BDC

Crescent Capital BDC, Inc is as a business development company private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.